Update from Revive Therapeutics on psilocybin clinical study
by CM Staff
The company will have exclusive access to key intellectual property from this study to support development, regulatory and commercial initiatives.
TORONTO — Revive Therapeutics Ltd. says it is currently evaluating the oral use of psilocybin to help treat methamphetamine use disorder with the University of Wisconsin-Madison, and it has also initiated a product development program under a feasibility agreement with LTS Lohmann Therapie-Systeme AG for the development of a Psilocybin thin film strip product.
“We continue to focus on building a specialty psilocybin-based product pipeline to treat mental illness, substance abuse and neurological disorders,” said Derrick Welsh, COO of Psilocin Pharma in a statement.
“The clinical data from this study will be used to support late-stage clinical trials with our oral psilocybin thin film strip product,” he added.
The clinical study to examine the potential use of psilocybin as a treatment for methamphetamine use disorder is done in collaboration with the University of Wisconsin-Madison’s School of Medicine and Public Health and School of Pharmacy.
Revive says the clinical data that is generated from the study will provide information on the safety, efficacy and dosing of oral psilocybin to support future FDA clinical studies for the company’s proposed oral psilocybin thin film strip product. In addition, the company will have exclusive access to key intellectual property from this study to support development, regulatory and commercial initiatives.
The company has initiated the product development program under a feasibility agreement with LTS Lohmann Therapie-Systeme AG to develop and manufacture a proprietary oral psilocybin thin film strip product for mental illness, substance abuse and neurological disorders. The company has developed prototypes of the oral psilocybin thin film strip product and says they are currently working to optimize them for use in upcoming IND-enabling studies.
